111 related articles for article (PubMed ID: 7927910)
1. Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis.
Huxham IM; Barlow AL; Lewis AD; Plumb J; Mairs RJ; Gaze MN; Workman P
Int J Cancer; 1994 Oct; 59(1):94-102. PubMed ID: 7927910
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines.
Bakker M; Renes J; Groenhuijzen A; Visser P; Timmer-Bosscha H; Müller M; Groen HJ; Smit EF; de Vries EG
Int J Cancer; 1997 Nov; 73(3):362-6. PubMed ID: 9359483
[TBL] [Abstract][Full Text] [Related]
3. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
Acta Med Okayama; 1992 Aug; 46(4):249-56. PubMed ID: 1442149
[TBL] [Abstract][Full Text] [Related]
5. The role of protein kinase C and the phosphatidylinositol cycle in multidrug resistance in human ovarian cancer cells.
Anderson L; Cummings J; Bradshaw T; Smyth JF
Biochem Pharmacol; 1991 Sep; 42(7):1427-32. PubMed ID: 1930266
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells.
Molinari A; Cianfriglia M; Meschini S; Calcabrini A; Arancia G
Int J Cancer; 1994 Dec; 59(6):789-95. PubMed ID: 7989120
[TBL] [Abstract][Full Text] [Related]
7. Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.
Beyer U; Rothern-Rutishauser B; Unger C; Wunderli-Allenspach H; Kratz F
Pharm Res; 2001 Jan; 18(1):29-38. PubMed ID: 11336350
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells.
Mazzoni A; Trave F
Oncol Res; 1993; 5(2):75-82. PubMed ID: 8364256
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and metabolism of a new anthracycline-containing fluorine (ME2303) in Lewis lung carcinoma-bearing mice.
Iigo M; Hoshi A; Kadosawa H; Fujigaki M
Jpn J Cancer Res; 1991 Nov; 82(11):1317-21. PubMed ID: 1752788
[TBL] [Abstract][Full Text] [Related]
10. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933.
Alaoui Jamali MA; Yin MB; Mazzoni A; Bankusli I; Rustum YM
Cancer Chemother Pharmacol; 1989; 25(2):77-83. PubMed ID: 2598402
[TBL] [Abstract][Full Text] [Related]
11. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.
Coley HM; Amos WB; Twentyman PR; Workman P
Br J Cancer; 1993 Jun; 67(6):1316-23. PubMed ID: 8099807
[TBL] [Abstract][Full Text] [Related]
12. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
14. Generation and characterization of a low-degree drug-resistant human tumor cell line.
Mazzoni A; Trave F; Russo P; Nicolin A; Rustum YM
Oncology; 1990; 47(6):488-94. PubMed ID: 2243668
[TBL] [Abstract][Full Text] [Related]
15. Intracellular mapping of 4'-deoxy-4'-iododoxorubicin in sensitive and multidrug resistant cells by electron spectroscopic imaging.
Diociaiuti M; Calcabrini A; Meschini S; Arancia G
Micron; 1997 Oct; 28(5):389-95. PubMed ID: 9519468
[TBL] [Abstract][Full Text] [Related]
16. Can cytotoxic activity of anthracyclines be related to DNA damage?
Nishiyama M; Horichi N; Mazouzi Z; Bungo M; Saijo N; Tapiero H
Anticancer Drug Des; 1990 Feb; 5(1):135-9. PubMed ID: 2317255
[TBL] [Abstract][Full Text] [Related]
17. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells.
Molinari A; Calcabrini A; Meschini S; Stringaro A; Del Bufalo D; Cianfriglia M; Arancia G
Int J Cancer; 1998 Mar; 75(6):885-93. PubMed ID: 9506534
[TBL] [Abstract][Full Text] [Related]
18. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
19. Confocal scanning microspectrofluorometry reveals specific anthracyline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells.
Belhoussine R; Morjani H; Millot JM; Sharonov S; Manfait M
J Histochem Cytochem; 1998 Dec; 46(12):1369-76. PubMed ID: 9815278
[TBL] [Abstract][Full Text] [Related]
20. Biological properties of ME2303 (FAD-104), a new anthracycline.
Omoto S; Kondo S; Fukatsu S; Takeuchi T; Umezawa K; Tsuchiya T; Umezawa S
Drugs Exp Clin Res; 1988; 14(7):435-9. PubMed ID: 3240704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
